AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 3.00 to 3.99 ng/mL
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 4.00 to 6.99 ng/mL
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 7.00 to 9.99 ng/mL
Trial: 16157829
Drug: PSA levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA levels 10.00 ng/mL or higher
Trial: 16157829
Drug: Initial PSA
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial PSA level less than 1 ng/mL
Trial: 7752005
Drug: Pulse doses
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse doses of dexamethasone, 0.5 mg/kg per day, divided twice daily for 3 days at 10-day intervals
Trial: 1578091
Drug: Vitamins B1,
RxNorm normalized name: vitamins B1,B2,B3,B5,and B6 100 mg-2 mg-100 mg-2 mg-2 mg/mL INJECTION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins B1, B2, and B6 (10 mg each)
Trial: 31125491
Drug: Olmutinib 100-300
RxNorm normalized name: olmutinib
DrugBank: Olmutinib (DB13164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmutinib 100-300 mg
Trial: 25189917
Drug: Complementary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary treatment with sodium selenite, proteolytic plant enzymes and Lc-lectin
Trial: 22519543
Drug: Subcutaneous nadroparin
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous nadroparin calcium (200 I.U./kg/day) for 6 weeks
Trial: 22519543
Drug: Oral pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pentoxifylline (control)
Trial: 17919374
Drug: Hypocaloric and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric and hypo-nitrogen parenteral nutrition (PN) with 18 (range 16-20) kcal x kg(‐1) x d(‐1) and nitrogen 0.10 (0.09-0.11) g x kg(‐1) x d(‐1)
Trial: 17919374
Drug: Hypocaloric and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric and hypo-nitrogen parenteral nutrition (PN)
Trial: 17919374
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving PN with 30 (28-32) kcal x kg(‐1) x d(‐1) and nitrogen 0.20 (0.19-0.21) g x kg(‐1) x d(‐1)
Trial: 10221413
Drug: Meropenem (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (0.5 g/8 h)
Trial: 10221413
Drug: Imipenem/cilastatin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (0.5 g/6 h)
Trial: 26521190
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg furosemide with HSS
Trial: 26521190
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg furosemide with HSS
Trial: 26521190
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg furosemide with HSS
Trial: 23480923
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5mg/kg) and ketamine (5mg/kg)
Trial: 23480923
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5mg/kg), acetaminophen (10mg/kg), and codeine (1mg/kg)
Trial: 22258912
Drug: 1-hour psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour psychoeducational group therapy
Trial: 22258912
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (no group therapy)
Trial: 19267777
Drug: MMF (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF (2 g/day)
Trial: 19267777
Drug: SRL (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRL (15 mg loading dose, 5 mg for 7 days followed by 2 mg/day)
Trial: 19267777
Drug: PRED dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRED dose reduction
Trial: 19267777
Drug: TAC drug
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAC drug exposure
Trial: 19267777
Drug: SRL drug
RxNorm normalized name: ExoSCRT Derma Signal Kit SRLV KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRL drug exposure
Trial: 7940710
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral acyclovir (800 mg 4 times a day) for 3 months
Trial: 7940710
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir (5 mg/kg twice a day for 14 days) followed by high dose oral acyclovir for 3 months
Trial: 7059416
Drug: Both compounds
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both compounds
Trial: 26081985
Drug: AmBisome 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome 10 mg/kg day one (single dose)
Trial: 26081985
Drug: AmBisome 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome 10 mg/kg day one and AmBisome 5 mg/kg day three (two doses)
Trial: 26081985
Drug: AmBisome 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome 10 mg/kg day one, and AmBisome 5 mg/kg days three and seven (three doses)
Trial: 26081985
Drug: AmBisome 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome 3 mg/kg/d for 14 days
Trial: 18442788
Drug: Dzherelo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dzherelo (50 drops twice per day)
Trial: 14700111
Drug: Diclofenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg 30-45 minutes preoperatively
Trial: 14700111
Drug: Placebo 30-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 30-45 minutes preoperatively and diclofenac 100 mg at induction
Trial: 1421679
Drug: Velnacrine 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine 450 mg/d
Trial: 1421679
Drug: Velnacrine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine 300 mg/d
Trial: 1421679
Drug: Velnacrine 225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine 225 mg/d
Trial: 1421679
Drug: Velnacrine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velnacrine 25 mg, 50 mg, 100 mg (twice daily)
Trial: 26809849
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (5-week supply: 3 weeks of 21 mg, 1 week of 14 mg, 1 week of 7 mg)
Trial: 26809849
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nicotine patches or other intervention)
Trial: 26222318
Drug: Linaclotide 145
RxNorm normalized name: LINACLOTIDE 145MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linaclotide 145 μg
Trial: 27903339
Drug: Goal-directed hemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed hemodynamic management group (G group, n=45)
Trial: 27903339
Drug: Goal-directed hemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed hemodynamic management group (G group)
Trial: 24794140
Drug: Detectable cTnI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detectable cTnI levels at both time points (≥0.01 µg/L)
Trial: 23061619
Drug: Monthly feedback
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly feedback on ventilator care bundle (VCB) compliance
Trial: 7963789
Drug: Codeine Contin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine Contin 100 mg every 12 hr
Trial: 7963789
Drug: Codeine Contin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine Contin 200 mg every 12 hr
Trial: 7963789
Drug: Codeine Contin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine Contin 300 mg every 12 hr
Trial: 7963789
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus codeine (600 mg/60 mg) every 6 hr
Trial: 7963789
Drug: Codeine Contin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine Contin 150 mg every 12 hr
Trial: 16192479
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg per day)
Trial: 21220619
Drug: 0.7-mg DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7-mg DEX implant
Trial: 21220619
Drug: 0.35-mg DEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.35-mg DEX implant
Trial: 19321584
Drug: High milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High milk consumption (4 x 236 mL/d)
Trial: 19321584
Drug: Low milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low milk consumption (1 x 236 mL/d)
Trial: 17042662
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg BID orally, 4 doses)
Trial: 17042662
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous fluid hydration
Trial: 12772815
Drug: Timolol gel-forming
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol gel-forming solution and latanoprost (tim/latan)
Trial: 3067105
Drug: Prostacyclin sodium
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostacyclin sodium (2.5-5.0 ng/kg/min) administered intravenously once daily during 2 weeks in 6-hour infusions
Trial: 3067105
Drug: Placebo (glycine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glycine buffer) administered intravenously once daily during 2 weeks in 6-hour infusions
Trial: 28754504
Drug: Health messaging
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health messaging intervention focused on provider communication about vaccination for HPV vaccine.
Trial: 28754504
Drug: Health messaging
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health messaging intervention focused on provider communication about vaccination for influenza vaccine.
Trial: 28494175
Drug: Plasmapheresis (supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmapheresis (supportive treatments + plasmapheresis)
Trial: 28494175
Drug: Supportive treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatments (Control group)
Trial: 21420417
Drug: ACWY-TT co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACWY-TT co-administered with DTaP-HBV-IPV/Hib
Trial: 9842243
Drug: Amikacin/metronidazole combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin/metronidazole combination
Trial: 8018396
Drug: Domperidone 60
RxNorm normalized name: domperidone 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 60 mg suppositories every 4 h
Trial: 8018396
Drug: Prochlorperazine 25
RxNorm normalized name: prochlorperazine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine 25 mg suppositories every 4 h
Trial: 2904464
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G and sulphadiazine for 5 days postoperatively
Trial: 23958073
Drug: EZ-Blocker
RxNorm normalized name: Jock-Eze
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EZ-Blocker
Trial: 25288038
Drug: Intermittent normobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent normobaric hyperoxia (InHO) for 4 hours daily for 2 weeks
Trial: 23960180
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance for 8 months, once every 2 months for a total of four doses
Trial: 18192898
Drug: 15-mg NRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg NRT transdermal patch for 8 weeks
Trial: 18192898
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (NRT)
Trial: 18192898
Drug: NRT transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT transdermal patch
Trial: 16582058
Drug: Brief therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief therapy
Trial: 12642264
Drug: Low-energy shock
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy shock wave treatment (3 applications of 2100 impulses)
Trial: 10955372
Drug: Celiprolol (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (0.30 mg/kg IV)
Trial: 10955372
Drug: Atenolol (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (0.15 mg/kg IV)
Trial: 1624927
Drug: Carbamazepine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (400 mg)
Trial: 1624927
Drug: Carbamazepine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (800 mg) and 400 mg
Trial: 29877227
Drug: Paprika xanthophylls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paprika xanthophylls (9 mg) administered daily for 5 weeks
Trial: 29877227
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered daily for 5 weeks
Trial: 26523330
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg triptorelin
Trial: 26523330
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg triptorelin
Trial: 23539724
Drug: 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg ACTH(1-24) intravenous stimulation test
Trial: 23539724
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg ACTH(1-24) intramuscular stimulation test
Trial: 20065185
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg/d plus risedronate 35 mg/wk orally (A + R)
Trial: 20065185
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg/d plus placebo (A + P)
Trial: 20065185
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg/d plus risedronate 35 mg/wk orally (A + R) in high-risk group
Trial: 15570651
Drug: tramadol/APAP (tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tramadol/APAP (tramadol 37.5 mg/acetaminophen 325 mg)
Trial: 9230863
Drug: Preincisional bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preincisional bupivacaine infiltration (40 mL of 0.25% bupivacaine 5 minutes before incision)
Trial: 9230863
Drug: Postincisional bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postincisional bupivacaine infiltration (40 mL of 0.25% bupivacaine immediately after approximation of the fascia)
Trial: 3028458
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ramipril
Trial: 29708589
Drug: Phenylephrine (α1-agonist)
RxNorm normalized name: phenylephrine 1.5 MG
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylephrine (α1-agonist) during exercise trials
Trial: 29708589
Drug: Dexmedetomidine (α2-agonist)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (α2-agonist) during exercise trials
Trial: 29708589
Drug: Resting and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resting and high flow trials with α1 and α2 agonists
Trial: 25703911
Drug: Intrarectal prilocaine‐lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal prilocaine‐lidocaine cream application
Trial: 25703911
Drug: INB +
RxNorm normalized name: Indinavir sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INB + intrarectal prilocaine‐lidocaine cream application (combined group)
Trial: 20606084
Drug: Imatinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 600 mg/d orally for 7 consecutive days (IM-positive group)
Trial: 18379217
Drug: Isometric training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isometric training (IMT) group: 20 exercises of 5-s isometric contraction of knee extensor, flexor, and ankle plantar flexor muscles, twice a day for 2 weeks
Trial: 10072029
Drug: nalbuphine 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 0.08 mg/kg
Trial: 10072029
Drug: meperidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 0.4 mg/kg
Trial: 2174653
Drug: pH-adjusted lignocaine
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-adjusted lignocaine solutions (1% lignocaine + 1 ml 8.4% sodium bicarbonate)
Trial: 6995193
Drug: Carnidazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnidazole (2 g single dose)
Trial: 29450747
Drug: Bifidobacterium breve
RxNorm normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium breve fermented milk (BFM) - 10 billion bacteria and Lactobacillus acidophilus - 1 billion bacteria, administered one pack per day for 48 weeks
Trial: 29450747
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered one pack per day for 48 weeks
Trial: 25041994
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) treatment, treatment arm 2
Trial: 25041994
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) treatment, treatment arm 1
Trial: 25041994
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) treatment, treatment arm 3
Trial: 20633465
Drug: Ephedra sinica
RxNorm normalized name: EPHEDRA SINICA STEM
DrugBank: Ephedra sinica stem (DB14747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedra sinica (pseudo-ephedrine 31.52 mg)
Trial: 20633465
Drug: Evodia rutaecarpa
RxNorm normalized name: evodia rutaecarpa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evodia rutaecarpa (evodiamine 6.75 mg, rutaecarpine 0.66 mg)
Trial: 10574639
Drug: Lupus anticoagulant
RxNorm normalized name: Lupus anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lupus anticoagulant positivity
Trial: 1953322
Drug: Ga‐As +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga‐As + He‐Ne laser treatment
Trial: 6958478
Drug: Beclomethasone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone 100 micrograms four times daily
Trial: 31861349
Drug: High-catechin group
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-catechin group (three daily doses of 57 mg catechins and 100 mg xanthan gum)
Trial: 31861349
Drug: Low-catechin group
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-catechin group (one daily dose of 57 mg catechins and 100 mg xanthan gum)
Trial: 31861349
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (0 mg catechins and 100 mg xanthan gum)
Trial: 29903459
Drug: Single-injection adductor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection adductor canal block (SACB) with 20 mL of 0.25% bupivacaine, 1.67 mcg/mL of clonidine, 2 mg of dexamethasone, 150 mcg of buprenorphine, and 2.5 mcg/mL of epinephrine
Trial: 29903459
Drug: Continuous adductor
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous adductor canal blockade (CACB) with 20 mL of 0.25% bupivacaine and 2.5 mcg/mL of epinephrine followed by an 8 mL/h infusion of 0.125% bupivacaine
Trial: 27124028
Drug: Intravenous anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthetics alone (control group)
Trial: 18831897
Drug: Eprosartan (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan (600 mg once daily)
Trial: 10085835
Drug: Simultaneous injection
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous injection
Trial: 10085835
Drug: Sequential injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential injection
Trial: 2261966
Drug: 15 mg.day‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg.day‐1 oral prednisone (PRD)
Trial: 7376025
Drug: Peroesophageal injection
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR GASTROESOPHAGEAL REFLUX DISEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroesophageal injection sclerotherapy using a modified, rigid Negus oesophagoscope under general anaesthesia
Trial: 7376025
Drug: Intravenous pitressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pitressin